Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Idorsia is a Swiss drugmaker that develops and sells medicines, most notably the insomnia pill QUVIVIQ.
Idorsia is a biopharmaceutical company that discovers and sells small-molecule drugs — pills and tablets made from chemical compounds rather than the large biological molecules that define newer classes of medicine. Its flagship product is QUVIVIQ, a once-nightly prescription pill for adults with chronic insomnia, a condition where people struggle to fall or stay asleep for months at a time. Doctors prescribe it; patients take it; insurers and health systems pay for it.
The company's real identity is as a research shop that bets on unproven biology. Idorsia was spun out of the Swiss giant Actelion in 2017 when that company was sold to Johnson & Johnson, and it inherited a deep pipeline of experimental compounds. The goal has always been to turn lab discoveries into approved medicines and then either sell them itself or partner with bigger firms. QUVIVIQ is the first big test of that model: a drug invented in-house, approved in the US and Europe, and now being rolled out commercially. That rollout is expensive and slow. Selling a new insomnia drug means building a sales force, persuading skeptical doctors, and haggling with insurers — all while burning cash on clinical trials for the rest of the pipeline. Idorsia has addressed this partly by licensing QUVIVIQ to partners in some regions and by striking a deal with Viatris to handle certain commercial activities, while it retains rights in key markets. The company has also had to manage a heavy debt load, refinancing and paying down obligations while waiting for sales to scale.
What makes Idorsia interesting is the gap between its science and its finances. The pipeline includes experimental drugs for rare diseases and cardiovascular conditions, and a single success there would transform the company. But biotech investing is a rollercoaster of trial results and regulatory decisions, and Idorsia's stock has swung hard on news of QUVIVIQ prescriptions, trial data, and cash runway. It is a company whose future hinges on whether its science can outrun its bills.
Saved answer · last researched 15 Nov 2026